Trial Profile
Phase 1 Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Alvespimycin (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 07 Nov 2009 Actual end date (August 2009) added as reported by ClinicalTrials.gov.
- 07 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Apr 2009 Planned end date changed from 1 Feb 2009 to 1 May 2009 as reported by ClinicalTrials.gov.